Phase 2 Melanoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by lab testing (biopsy or cell sample) to have a type of melanoma called mucosal or acral melanoma that cannot be surgically removed, has spread to nearby areas, or has spread to other parts of the body (stage III or IV).
• People who have not yet received any systemic (whole-body) treatment for their unresectable or metastatic melanoma; prior treatment given before or after surgery is allowed, unless the melanoma got worse during that treatment or within 6 months of stopping it.
• People who have at least one measurable area of cancer that can be tracked by imaging scans (such as a CT or MRI scan) according to standard measurement guidelines.
• People who are reasonably active and able to care for themselves, rated 0 or 1 on a standard physical functioning scale (confirm with trial site).
• People whose doctors expect them to live for at least 3 months.
• Women who could become pregnant, and men whose partners could become pregnant, who agree to use reliable contraception throughout the treatment period and for 6 months after treatment ends.
• Women who are breastfeeding who agree to stop breastfeeding for the entire treatment period and for 6 months after treatment ends.

Who may not be able to join:

• Women who are pregnant, or who plan to become pregnant during the study or within 6 months after the last dose of the study drug.
• People who have brain or spinal metastases (cancer spread to the central nervous system) that are currently active or causing symptoms.
• People whose recent blood test results show certain blood cell abnormalities, such as low red blood cells, low white blood cells, or low platelets (confirm specific values with trial site).
• People whose recent blood tests show certain liver or kidney abnormalities, such as elevated liver enzymes or bilirubin, reduced kidney function, or low albumin (a blood protein) (confirm specific values with trial site).
• People whose blood clotting test results are outside the acceptable range before starting the study, unless they are already on a stable dose of blood-thinning medication and still fall within allowed limits (confirm with trial site).
• People who have had a blood clot, deep vein thrombosis, or pulmonary embolism (blood clot in the lungs) in the 4 weeks before starting the study, unless the condition has been well treated and is considered stable by the treating doctor.
• People who have uncontrolled bleeding or a known tendency to bleed.
• People who have significant heart or stroke-related disease (confirm with trial site).
• People who have a history of certain lung conditions — such as interstitial pneumonia, pulmonary fibrosis, or radiation-related lung damage — that required treatment with steroids or other medications, or who have severely reduced lung function.
• People who have had an active autoimmune disease requiring ongoing systemic treatment within the past 2 years; hormone replacement therapies (such as thyroid hormone or insulin) are not considered systemic treatment for this purpose.

Important: Always verify eligibility with the trial site directly before applying.